What are analysts' predictions for HAE stock?
Equity research analysts covering Haemonetics Corporation (HAE) maintain a favorable consensus rating, predominantly leaning toward a buy recommendation based on the company's strong positioning within the global medical device, blood management, and healthcare diagnostics sectors. Financial predictions highlight steady revenue growth driven by expanding adoption of its advanced hemostasis management systems, plasma collection equipment, and hospital-based procedural technologies. Consensus twelve-month price targets point to healthy double-digit upside potential from current trading levels, supported by disciplined margin expansion, robust recurring revenue streams from consumable medical supplies, and effective operational execution across its international markets.
Related FAQs
Haemonetics Corporation was officially founded in 1971 by visionary biomedical inventor Dr. Allen Latham, Jr., who revolutionized blood processing technology by developing the world's first automated blood separator.
Haemonetics Corporation maintains a strong reputation as an innovative healthcare technology and medical device enterprise dedicated to providing advanced solutions for blood and plasma collection, surgical hemostasis, and hospital transfusion manage...
Hana Bank is a colossal, premier commercial banking institution headquartered in Seoul, South Korea, operating as a flagship subsidiary under the Hana Financial Group.
Hagerty’s standard collector car insurance is designed to provide coverage for vehicle loss or damage resulting from accidents, fire, theft, or natural disasters, but it does not typically cover mechanical breakdowns or engine failures due to normal ...
Haemonetics Corporation (HAE) is a global healthcare company that provides innovative medical solutions for blood management. Its products and services are used for blood collection, testing, separation, and transfusion processes.
Haemonetics Corporation is a prominent global healthcare company dedicated to providing advanced medical solutions, specifically focusing on blood management, plasma collection, and surgical technologies.
Haemonetics functions primarily as a specialized medical technology and healthcare equipment manufacturing enterprise rather than a traditional drug-discovery biotechnology firm.
Haemonetics Corporation is frequently evaluated by healthcare sector analysts as a solid long-term investment, supported by steady demand for its specialized blood management technologies, plasma collection systems, and hospital surgical solutions.
Harmonic Drive SE maintains a specialized industrial manufacturing workforce of approximately one,three hundred eighty employees focusing on high-precision gear solutions, drive mechanisms, and motion control components.
Hawkins Inc (HWKN) has demonstrated stellar and resilient stock performance recently, trading strongly within the upper tier of its 52-week range and rewarding long-term shareholders.
Haemonetics (HAE) stock has shown significant performance over the past year, reflecting its growth in the medical technology sector. As of August 2, 2026, the stock was trading at $85.54, with a 52-week trading range spanning from $47.32 to $87.32.